Abbott Acquires Bigfoot Biomedical
September 5, 2023
Abbott has entered a definitive agreement to acquire Bigfoot Biomedical, a developer of smart insulin management systems that integrate continuous glucose monitoring with connected insulin pen caps and a cloud-based provider portal. The acquisition will combine Abbott’s FreeStyle Libre CGM technology with Bigfoot’s dosing-capable pen cap platform to further develop personalized, connected diabetes care solutions; the deal is expected to close in Q3 2023 and financial terms were not disclosed.
- Buyers
- Abbott
- Targets
- Bigfoot Biomedical
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Dude Solutions Acquires Bigfoot (Bigfoot CMMS)
January 1, 2020
Software
Dude Solutions has acquired Bigfoot, a provider of cloud-based EAM/CMMS software (Bigfoot CMMS), expanding its portfolio of operations and asset management solutions. Dude Solutions — backed by Warburg Pincus — completed the transaction with Software Equity Group serving as exclusive advisor to Bigfoot.
-
Tandem Diabetes Care Acquires Capillary Biomedical
July 21, 2022
Medical Devices
Tandem Diabetes Care, Inc. has acquired Capillary Biomedical, a developer of extended-wear insulin infusion set technology. The acquisition (terms not disclosed) brings Capillary's infusion-set R&D into Tandem's product portfolio to expand infusion set options and advance extended-wear solutions for insulin pump users.
-
Peak Seven Acquires Bigfoot Web
March 14, 2022
Marketing & Advertising
Peak Seven, a Boca Raton full-service ad agency, has acquired Bigfoot Web, a Denver-based digital development and advertising agency. The acquisition expands Peak Seven's geographic reach to the western United States, broadens its service offering (branding, video production, stronger digital marketing and development), and will add jobs in both Denver and Boca Raton.
-
Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics
October 20, 2021
Biotechnology
Big Cypress Acquisition Corp., a Nasdaq-listed special purpose acquisition company, received shareholder approval to complete a business combination with clinical-stage biopharmaceutical company SAB Biotherapeutics. Upon closing, the combined company will be named SAB Biotherapeutics, Inc. and its common stock and warrants are expected to trade on Nasdaq, providing SAB with public-market capital to advance its antibody immunotherapy platform and clinical programs.
-
Insulet Corporation Acquires Assets of Automated Glucose Control LLC (AGC)
February 14, 2023
Medical Devices
Insulet Corporation acquired the assets and license portfolio of Automated Glucose Control LLC (AGC), a Palo Alto–based developer of automated insulin delivery technology. The asset purchase (approx. $25 million) transfers AGC’s UC Santa Barbara–licensed intellectual property and related technology to Insulet to accelerate development of its Omnipod automated insulin delivery systems.
-
BigHat Biosciences Acquires Frugi Biotechnology
March 28, 2022
Biotechnology
BigHat Biosciences has acquired Frugi Biotechnology to integrate Frugi's cell-free protein synthesis (CFPS) technology into BigHat's AI/ML-enabled drug discovery platform. The acquisition brings CFPS capabilities and Frugi's team in-house to help BigHat scale its antibody synthesis and discovery workflows; terms were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.